医学
依杜沙班
心房颤动
蒂米
华法林
危险系数
冲程(发动机)
内科学
心脏病学
随机对照试验
心肌梗塞
经皮冠状动脉介入治疗
置信区间
达比加群
机械工程
工程类
作者
Eri Kato,Robert P. Giugliano,Christian T. Ruff,Yukihiro Koretsune,Takeshi Yamashita,Róbert Gábor Kiss,Francesco Nordio,Sabina A. Murphy,Takeshi Kimura,James Jin,Hans Lanz,Michele Mercuri,Eugene Braunwald,Elliott M. Antman
标识
DOI:10.1161/jaha.116.003432
摘要
Background Elderly patients with atrial fibrillation are at higher risk of both ischemic and bleeding events compared to younger patients. In a prespecified analysis from the ENGAGE AF ‐ TIMI 48 trial, we evaluate clinical outcomes with edoxaban versus warfarin according to age. Methods and Results Twenty‐one thousand one‐hundred and five patients enrolled in the ENGAGE AF ‐ TIMI 48 trial were stratified into 3 prespecified age groups: <65 (n=5497), 65 to 74 (n=7134), and ≥75 (n=8474) years. Older patients were more likely to be female, with lower body weight and reduced creatinine clearance, leading to higher rates of edoxaban dose reduction (10%, 18%, and 41% for the 3 age groups, P <0.001). Stroke or systemic embolic event (1.1%, 1.8%, and 2.3%) and major bleeding (1.8%, 3.3%, and 4.8%) rates with warfarin increased across age groups ( P trend <0.001 for both). There were no interactions between age group and randomized treatment in the primary efficacy and safety outcomes. In the elderly (≥75 years), the rates of stroke/systemic embolic event were similar with edoxaban versus warfarin (hazard ratio 0.83 [0.66–1.04]), while major bleeding was significantly reduced with edoxaban (hazard ratio 0.83 [0.70–0.99]). The absolute risk difference in major bleeding (−82 events/10 000 pt‐yrs) and in intracranial hemorrhage (−73 events/10 000 pt‐yrs) both favored edoxaban over warfarin in older patients. Conclusions Age has a greater influence on major bleeding than thromboembolic risk in patients with atrial fibrillation. Given the higher rates of bleeding and death with increasing age, treatment of elderly patients with edoxaban provides an even greater absolute reduction in safety events over warfarin, compared to treatment with edoxaban versus warfarin in younger patients. Clinical Trial Registration URL : https://www.clinicaltrials.gov/ . Unique identifier: NCT 00781391.
科研通智能强力驱动
Strongly Powered by AbleSci AI